… of mAbs for cancer therapy remains very high. … latest Trial Watch dealing with mAbs and
cancer therapy are still ongoing.Citation 6 The results of these large, randomized clinical trials …

… Table 2 summarizes the mAbs that are currently approved for use in cancer therapy. In this
Trial Watch, we will discuss the clinical progress of mAbs that entered clinical trials for this indi…

… Update on Clinical Trials When our latest Trial Watch dealing with the use of recombinant
TAAs or peptides thereof as anticancer vaccines was submitted for publication to …

… In line with the scope of our Trial Watch (see above), we will not consider these studies
further. Rather, we will focus on experimental mAbs or FDA-approved mAbs employed as off-…

… Recently, CGs have been suggested to exert potent antineoplastic effects, notably as
they appear to increase the immunogenicity of dying cancer cells. In this Trial Watch, we …

… In this Trial Watch, we will summarize the results of recent clinical trials that have evaluated/are
… purified peptides or full-length proteins as therapeutic interventions against cancer. …

… of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer.
As an update to the latest Trial Watch dealing with this exciting field of research (October 2012…

… The following clinical studies discussed in our previous Trial Watch dealing with oncolytic
virotherapyCitation 198 have changed status during the last 12 mo. NCT00602277, …

… In this Trial Watch, we summarize recent preclinical and clinical progress on the … in
peer-reviewed journals after the publication of our latest Trial Watch on the same topic (March 2015).…

… In this Trial Watch, we will discuss the results of recent clinical trials that have evaluated/are …
the scope of the present Trial Watch and can be found in refs. Citation9 and Citation11. …